MediWound Ltd. (MDWD)
| Market Cap | 212.96M +21.7% |
| Revenue (ttm) | 16.96M -16.1% |
| Net Income | -23.88M |
| EPS | -2.10 |
| Shares Out | 12.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,380 |
| Open | 16.57 |
| Previous Close | 16.72 |
| Day's Range | 16.26 - 16.92 |
| 52-Week Range | 14.90 - 22.51 |
| Beta | 0.15 |
| Analysts | Strong Buy |
| Price Target | 36.00 (+117.26%) |
| Earnings Date | May 20, 2026 |
About MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other ... [Read more]
Financial Performance
In 2025, MediWound's revenue was $16.96 million, a decrease of -16.14% compared to the previous year's $20.22 million. Losses were -$23.88 million, -20.99% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for MDWD stock is "Strong Buy" and the 12-month stock price target is $36.0.
News
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive bi...
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL ® Findings support o...
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic...
MediWound Files Annual Report on Form 20-F
MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announce...
MediWound Earnings Call Transcript: Q4 2025
2025 saw major clinical and manufacturing milestones, with EscharEx and NexoBrid advancing and revenue guidance reaffirmed for 2026–2028. Despite lower 2025 revenue due to US government delays, the balance sheet was strengthened and long-term growth drivers remain intact.
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
EscharEx ® Phase III VALUE trial advancing as planned Expanded NexoBrid ® manufacturing facility operational ; regulatory approvals expected in 2026 $17 million revenue in 2025 ; $54 million in cash a...
MediWound Transcript: TD Cowen 46th Annual Health Care Conference
NexoBrid is expanding capacity for global burn care markets, while EscharEx is advancing through late-stage trials targeting chronic wounds, with significant clinical advantages over competitors and projected peak U.S. sales of $831 million. Key milestones in 2024 include manufacturing expansion and phase III interim results for EscharEx.
MediWound Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
A late-stage biologic firm highlighted strong commercial growth for its burn therapy and advanced progress for its chronic wound asset, supported by robust financials and government partnerships. Key catalysts include manufacturing expansion, regulatory milestones, and a pivotal Phase III readout for EscharEx by late 2026.
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5 th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- Med...
MediWound to Present at Upcoming Investor Conferences
MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17 , 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t...
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
MediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
MediWound Reports New Clinical Data Demonstrating NexoBrid ® 's Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
MediWound Earnings Call Transcript: Q3 2025
Q3 2025 saw 23% revenue growth, improved margins, and a narrowed net loss, driven by strong EscharEx and NexoBrid progress. Expanded manufacturing and $30M financing support future growth, while regulatory and contract timing remain key uncertainties.
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid ® Facility; Full Operational Capacity Expected by Year-End 2025 B...
MediWound to Report Third Quarter 2025 Financial Results
MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd.
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid ®
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
MediWound Expands Global Reach with Marketing Approval of NexoBrid ® in Australia
MediWound Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Enzymatic wound care products are advancing, with a pivotal phase 3 study for venous leg ulcers and major manufacturing expansion underway. Key catalysts include BARDA contracts, new facilities, and interim clinical results, while strong partnerships and financial stability support growth.
MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
MediWound's NexoBrid ® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global lead...
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, ...
MediWound Earnings Call Transcript: Q2 2025
Q2 2025 saw strong revenue growth, expanded clinical collaborations, and progress on manufacturing scale-up. NexoBrid U.S. sales rose 52% year-over-year, while S-CoreX trials advanced and new funding was secured. Regulatory approvals and increased capacity are expected in 2026.
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid ® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strate...
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
MediWound Announces New EscharEx ® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
MediWound to Report Second Quarter 2025 Financial Results
MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd.